The proteome is a major determinant of the behaviour of cells and tissues, including cancers, and it is therefore expected that the proteomic analysis of cancers will assist clinicians to predict outcomes and choose the most effective treatment for individual patients. However, for a variety of technical reasons, quantitative proteomic analyses are not yet in routine clinical use. This talk will briefly describe the proteomic techniques developed by the ProCan® program that can readily fit into existing clinical diagnostic workflows, are scalable, and generate reproducible data. Second, progress will be described towards the development of an evidence base for interpretation of cancer proteomic data through analyses of cancer samples and associated clinical outcome data from patient cohorts representing a wide range of cancer types - paediatric and adult - in collaboration with many dozens of cancer research groups in Australia and other countries with comparable health systems.